Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has earned an average rating of “Hold” from the six analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. […]
StockNews.com upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) from a sell rating to a hold rating in a research report sent to investors on Friday. Separately, JPMorgan Chase & Co. lowered their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an underweight rating on the stock in a report on […]
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Hold" from Analysts theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its price objective lowered by HC Wainwright from $30.00 to $28.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other analysts have also weighed in on ENTA. JPMorgan Chase & Co. lowered shares […]
Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its price target trimmed by JMP Securities from $42.00 to $23.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock. Other research analysts have also recently issued reports about the company. Jefferies Financial Group […]